Hopital Huriez — Clinical Trial Site

30 Registered trials

13 Currently recruiting

Organisation

Hopital Huriez

Location

Lille Cedex, France

Identifier

ORG-100033322

Address

1 Place De Verdun, 59045, France

Departments

#1105: Dermatology
#1712:Rhumatology
#2200: Internal Medicine
59
7006: Medical Oncology
chirurgie digestive
Chirurgie digestive et transplantation
Department of Digestive Diseases and Nutrition
Digestive and oncological surgery
Gastroenterology
Hématologie
Hematology
Infectious Diseases
Maladie de l’Appareil Digestif et Oncologie Médicale
Médecine Interne
Medical Oncology
Nephrology
Nuclear Medecine
service d'hématologie
Service de Médecine interne
Service des Maladies de l’Appareil Digestif et de la Nutrition
Service des Maladies du sang
Service Maladies de l’Appareil Digestif et de la Nutrition

Clinical trials at this site (30)

Search interface

A Phase 2, single arm Multicenter, Study testing Mezigdomide, Carfilzomib, and Dexamethasone (480Kd) in Participants with Relapsed or Refrac… Pending

2025-521090-14-00 Patients with relapsed/refractory symptomatic multiple 4
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorect… Pending

2025-523521-18-00 Metastatic Colorectal Cancer 5
Screening for subclinical antibody mediated rejection and efficacy of belatacept in the context of de novo donor specific antibody after kid… Recruiting

2024-516527-13-00 Kidney transplantation 11 2026-05-27
Phase 3 Study of T-DXd and Rilvegostomig versus Standard of Care in Advanced HER2-expressing Biliary Tract Cancer Recruiting

2023-508057-19-00 Advanced HER2-expressing Biliary Tract Cancer 5 2025-09-23
Ph 3a, linerixibat, Long term safety and tolerability study in pts with PBC Recruiting

2023-503465-33-00 Cholestasis 5 2020-07-03
A phase III placebo-controlled efficacy and safety study of mocravimod as an adjunctive and maintenance treatment in AML patients undergoing… Recruiting

2024-512752-38-00 Adjunctive and maintenance treatment to HCT 5 2025-09-09
A study to assess the efficacy and safety of efgartigimod PH20 SC in adults with systemic sclerosis (eSScape) Recruiting

2024-514539-67-00 Systemic Sclerosis 4 2025-06-27
MAINTAIN-POP: EXL01 and prevention of post-operative recurrence of Crohn's disease Recruiting

2024-511357-22-00 Crohn's disease 4 2025-03-31
FIRST LINE CHEMOTHERAPY FOR METASTATIC GASTRO ENTERO PANCREATIC NEUROENDOCRINE CARCINOMA Recruiting

2024-515300-39-00 METASTATIC GRADE 3 POORLY DIFFERENTIATED NEUROENDOCRINE 4 2024-10-18
Neoadjuvant Chemotherapy for Obstructive Colon cancER first Treated by cOlostomy : A randomized phase III trial - COnCERTO (French 01-18) 20… Recruiting

2024-516456-17-00 patients admitted for an obstructive colon cancer 5 2024-05-07
A Study to Compare the Efficacy and Safety of Glofitamab as a Single Agent Versus Investigator’s Choice in Patients with Relapsed/Refractory… Recruiting

2023-503206-37-00 Mantle Cell Lymphoma (MCL) 5 2023-11-20
FLUCLORIC - Randomized multicentric Phase III study comparing the efficacy of two reduced intensity conditioning regimens (clofarabine/busul… Recruiting

2022-502019-12-00 acute myeloid leukemia 5 2023-09-14
A study to evaluate efficacy and safety of an investigational drug named volixibat in patients with itching caused by primary biliary cholan… Recruiting

2023-504660-41-00 Cholestatic Pruritus in Patients with Primary Biliary C 4 2022-07-11
CAR T-cell therapy long term follow-up Recruiting

2023-508128-37-00 All patients who have been treated with Novartis or Pen 5 2017-07-19
Prospective multicenter randomized controlled double-blind label study of the prophylaxis of recurrent pouchitis after fecal microbiota tran… Ended

2024-517078-52-00 Patients operated with an IPAA for ulcerative colitis w 5 2026-01-19
A 52-week multi-center, randomized, double-blind, placebo controlled, basket study with an open-label extension to investigate the efficacy,… Ended

2023-505739-12-01 Chronic Inducible Urticaria (CINDU) 5 2024-09-30
A study of continued treatment with regorafenib in participants with solid tumors who have participated in other Bayer studies Ended

2023-507084-19-00 Solid malignant tumors 4 2024-03-07
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjögren’… Ended

2022-502966-26-01 Sjögren’s syndrome 5 2023-10-27
A phase 3 clinical trial of a new combination treatment, domvanalimab and zimberelimab, plus chemotherapy, for people with an upper gastroin… Ended

2023-507522-16-00 Metastatic Esophageal or Gastric Cancer 5 2023-05-22
MSI/dMMR tumors in perioperative setting Ended

2024-518127-30-00 MSI/dMMR tumors or EBV+ gastric cancer 4 2021-11-26
Efficacy and Safety of Afimetoran Compared with Placebo in Participants with Active Systemic Lupus Erythematosus Ended

2023-504320-25-00 Active Systemic Lupus Erythematosus 4 2021-11-25
Exploratory study evaluating the relevance of [68Ga]Ga-PentixaFor for initial staging and therapeutic evaluation of symptomatic multiple mye… Ended

2024-516752-18-00 Multiple myeloma 4 2021-09-21
A Phase 3, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study of Inebilizumab Efficacy and Safety in IgG4-Related Disease. Ended

2023-508290-81-00 Immunoglobulin G4-related disease (IgG4-RD) 5 2020-12-18
Rollover study for continued safety and tolerability in subjects treated with spartalizumab alone or in combination with other study treatme… Ended

2023-508841-42-00 Different types of advanced cancer 3 2019-10-30